Sarkar Sauradeep, Philip Vinu Joe, Cherukuri Sai Kiran, Chacko Ari George, Chacko Geeta
Department of Neurological Sciences, Christian Medical College, Vellore, India.
Section of Neuropathology, Department of Pathology, Christian Medical College, Vellore, Tamil Nadu, 632004, India.
Acta Neurochir (Wien). 2017 Nov;159(11):2179-2186. doi: 10.1007/s00701-017-3223-z. Epub 2017 Jun 1.
The World Health Organization (WHO) defines atypical pituitary adenomas as tumours with a MIB-1 labelling index ≥3%, p53 positivity and increased mitotic activity. Although a few reports have described the clinical and radiological correlates of atypia in pituitary adenomas, its impact on postoperative outcomes is not clearly defined.
We reviewed preoperative and postoperative records of patients undergoing surgery for pituitary adenomas. Postoperative outcomes for functional adenomas (FPAs) were assessed according to contemporary definitions of remission and recurrence. For non-functional pituitary adenomas (NFPAs), extent of resection and disease progression were defined on the basis of postoperative magnetic resonance imaging.
Of 394 patients included for analysis, 29 cases (7.4%) fulfilled criteria for atypia. Patients with atypical tumours were significantly younger than those with typical adenomas. Remission was possible in 47.4% of FPAs, and was unrelated to the presence of atypia. In NFPAs, local invasiveness was negatively associated with extent of resection (OR, 0.255; 95% CI, 0.086-0.753; p < 0.001). In 93 NFPAs followed postoperatively with serial imaging over a mean duration of 37.5 months, disease progression/recurrence was significantly associated with the presence of atypia (OR, 5.058; 95% CI, 1.273-20.098; p = 0.021) on multivariate analysis.
Patients with atypical non-functional pituitary adenomas are at risk for postoperative recurrence and disease progression, suggesting a need for adjuvant therapy. However, only a small fraction of pituitary tumours demonstrate atypia, as defined by the WHO, limiting its clinical utility.
世界卫生组织(WHO)将非典型垂体腺瘤定义为有丝分裂指数(MIB-1)≥3%、p53阳性且有丝分裂活性增加的肿瘤。尽管有一些报告描述了垂体腺瘤非典型性的临床和影像学相关因素,但其对术后结果的影响尚不清楚。
我们回顾了接受垂体腺瘤手术患者的术前和术后记录。根据缓解和复发的当代定义评估功能性腺瘤(FPA)的术后结果。对于无功能性垂体腺瘤(NFPA),根据术后磁共振成像确定切除范围和疾病进展情况。
纳入分析的394例患者中,29例(7.4%)符合非典型性标准。非典型肿瘤患者比典型腺瘤患者明显年轻。47.4%的FPA有可能缓解,且与非典型性的存在无关。在NFPA中,局部侵袭性与切除范围呈负相关(OR,0.255;95%CI,0.086-0.753;p<0.001)。在93例术后平均随访37.5个月的NFPA中,多因素分析显示疾病进展/复发与非典型性的存在显著相关(OR,5.058;95%CI,1.273-20.098;p=0.021)。
非典型无功能性垂体腺瘤患者有术后复发和疾病进展的风险,提示需要辅助治疗。然而,按照WHO的定义,只有一小部分垂体肿瘤表现为非典型性,限制了其临床应用价值。